Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.68 |
| ▸ | TSHR | P16473 | 1/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 4/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | BACE1 | P56817 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL712713 | 0.83 | MAPT (0.70) | KMT2AHSD17B10TSHRMAPK1MAPT | |
| Hydrochloric Acid SCHEMBL712415 | 0.81 | MAPT (0.73) | KMT2AHSD17B10TSHRMAPK1MAPT | |
| SCHEMBL13692159 | 0.81 | KMT2A (0.68) | KMT2AHSD17B10TSHRMAPK1MAPT | |
| SCHEMBL1703637 | 0.79 | KMT2A (0.63) | KMT2AHSD17B10TSHRMAPK1MAPT | |
| SCHEMBL18235821 | 0.79 | KMT2A (0.66) | KMT2AHSD17B10TSHRMAPK1MAPT | |
| SCHEMBL29442842 | 0.79 | KMT2A (0.63) | KMT2AHSD17B10TSHRMAPK1MAPT | |
| SCHEMBL3591944 | 0.79 | HSD17B10 (0.61) | KMT2AHSD17B10TSHRMAPK1MAPT | |
| SCHEMBL3593783 | 0.78 | MAPT (0.68) | KMT2AHSD17B10TSHRMAPK1MAPT | |
| SCHEMBL3611556 | 0.78 | MAPT (0.97) | KMT2AHSD17B10TSHRMAPK1MAPT | |
| SCHEMBL19268474 | 0.78 | MAPT (0.68) | KMT2AHSD17B10TSHRMAPK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024145483-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CANCER AND METHODS OF MAKING AND USING THE SAME | HTG MOLECULAR DIAGNOSTICS, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| US-10919885-B2 | Compounds and uses thereof | YUMANITY THERAPEUTICS, INC. (US) | 2021-02-16 | — | — | US | disclosed |
| US-20190330198-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2019-10-31 | — | — | US | disclosed |
| US-20100041696-A1 | Compounds | SMITHKLINE BEECHAM CORPORATION | 2010-02-18 | — | — | US | disclosed |
| US-20100041696-A1 | Compounds | SMITHKLINE BEECHAM CORPORATION | 2010-02-18 | — | — | US | disclosed |
| US-20100041696-A1 | Compounds | SMITHKLINE BEECHAM CORPORATION | 2010-02-18 | — | — | US | disclosed |
| EP-2144895-A2 | ISOQUINOLINECARBOXAMIDES AS INHIBITORS OF STEAROYL-COA DESATURASE (SCD) | SmithKline Beecham Corporation (US) | 2010-01-20 | — | — | EP | disclosed |
| WO-2009056556-A1 | SUBSTITUTE 1, 6-NAPHTHYRIDINES FOR USE AS SCD INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-05-07 | — | — | WO | disclosed |
| WO-2009056556-A1 | SUBSTITUTE 1, 6-NAPHTHYRIDINES FOR USE AS SCD INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-05-07 | — | — | WO | disclosed |
| WO-2008074824-A2 | ISOQUINOLINECARBOXAMIDES AS INHIBITORS OF STEAROYL-COA DESATURASE (SCD) | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008074824-A2 | ISOQUINOLINECARBOXAMIDES AS INHIBITORS OF STEAROYL-COA DESATURASE (SCD) | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041696-A1 | Compounds | CYP11B2, SCD, CYP3A5 | KMT2A 3500/4885HSD17B10 326/4885TSHR 4213/4885 |
| US-10919885-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | KMT2A 2479/4885HSD17B10 1103/4885TSHR 4679/4885 |
| US-20190330198-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | KMT2A 2479/4885HSD17B10 1103/4885TSHR 4679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.